Health Canada has suspended sales of Allergan’s Biocell breast implants due to a higher incidence of a rare breast cancer in patients with macro-textured breast implants than other implants.
The Allergan (NYSE: AGN) Biocell breast implants are the only macro-textured implants available in Canada. The regulatory agency instituted the ban based on the results of a 2017 safety review on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Allergan has agreed to voluntarily recall unused Biocell devices from the Canadian market, according to Health Canada. Allergan’s other breast implant products are not affected by this decision.